Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes?
University of Alabama at Birmingham · NCT07546409
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 60–75 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 20
- US sites recruiting
- 2
- Study start
- May 20, 2025
- Record last updated
- July 2, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Brief Summary
The goal of this clinical trial is to learn whether older adults with prediabetes, but no diagnosed cognitive impairment, show early changes in brain energy use and thinking speed compared to older adults with normal blood sugar levels. The study will also test whether a single dose of an exogenous ketone supplement can improve brain energy use and cognitive processing speed.
The main questions it aims to answer are
Do older adults with prediabetes have lower brain glucose uptake and slower cognitive processing speed compared to those with normal glucose levels?
Does a single dose of an exogenous ketone monoester supplement improve cognitive processing speed and brain glucose uptake?
Researchers will compare older adults with prediabetes to older adults with normal glucose levels to determine whether differences exist in brain glucose metabolism and cognitive performance. In a subset of participants, researchers will also compare brain and cognitive outcomes before and after consuming a ketone monoester supplement (DeltaG, Oxford, England).
Participants will
Complete metabolic testing to determine glucose status
Undergo brain imaging using fluorodeoxyglucose positron emission tomography combined with magnetic resonance imaging (18FDG-PET/MRI) while performing a cognitive processing speed task
Consume a single dose of a commercially available ketone monoester supplement during one study visit
Complete cognitive testing during imaging to measure processing speed and brain activity
The results of this study will help determine whether early metabolic dysfunction is linked to reduced brain energy use and whether ketones can temporarily support brain function in individuals at risk for dementia.
Being studied: Ketone Monoester (KE); Placebo
Conditions: Prediabetes; Healthy (Controls)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 60 to 75 years
- Able to provide written informed consent
- Fluent in English
- No diagnosed cognitive impairment or dementia
Classified as either
- Prediabetes (based on American Diabetes Association criteria), or Normal glucose regulation (control group)
- Medically stable and cleared to undergo positron emission tomography and magnetic resonance imaging
- Willing to comply with study procedures, including metabolic testing, supplement ingestion, and neuroimaging
Exclusion Criteria
- Diagnosis of mild cognitive impairment, dementia, or other neurodegenerative disorder
- Diagnosis of type 1 diabetes or type 2 diabetes
- Use of glucose-lowering medications (e.g., insulin, metformin, glucagon-like peptide-1 receptor agonists)
- History of major neurological disorder (e.g., stroke, traumatic brain injury with loss of consciousness >30 minutes, epilepsy, multiple sclerosis)
- Major psychiatric disorder not stable on treatment
- Uncontrolled hypertension or significant cardiovascular disease
- Severe renal, hepatic, or gastrointestinal disease that may affect supplement metabolism
- Contraindications to magnetic resonance imaging (e.g., non-compatible implanted devices, severe claustrophobia)
Recruiting US locations
UAB Comprehensive Cancer Center
Birmingham, AL 35205
Site contact: Sarah K Sweatt, PhD · 205-975-5398 · sksweatt@uab.edu
Webb Nutrition Sciences Building
Birmingham, AL 35205
Site contact: Sarah K Sweatt, PhD · 205-975-5398 · sksweatt@uab.edu
Study contacts (from the official record)
- Katherine Sweatt, PhD · 205-975-5398 · sksweatt@uab.edu
Similar studies in Alabama
All diabetes studies in Alabama →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Birmingham, AL + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 2
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Biomea Fusion Inc.
- Location
- Birmingham, AL + 19 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
Sonavex, Inc.
- Location
- Dothan, AL + 19 other US sites
- Eligibility basics
- Ages 18–84
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Anniston, AL + 57 other US sites
- Eligibility basics
- Ages 18–80